Episode Summary In this episode of LIMBWatch, we go beyond the wound itself to explore the science, clinical challenges, and innovations shaping the future of limb preservation. We are joined by the team behind Lavior, including biomedical scientist and Chief Scientific Officer Dr. David Warren, wound care and hyperbaric medicine specialist Dr. Hanley, wound care podiatrist Dr. Sukoff, and National Sales Director Ashlyn Tapley. The conversation explores how Lavior was inspired by the healing properties of Inula viscosa, a medicinal plant with centuries of traditional use, and how the company developed a bioengineered hydrogel designed to address key challenges in chronic wound healing. We dive into the inflammatory phase of wound healing, antimicrobial and anti-inflammatory activity, bioactive compounds, wound-bed preparation, diabetic foot ulcers, surgical wounds, burns, pressure injuries, venous ulcers, and other complex wounds. The discussion also examines how Lavior is being used alongside negative pressure wound therapy, collagen, alginate, skin substitutes, PRP, total contact casting, and other wound-care modalities. Importantly, this episode goes beyond any single product. We discuss the fundamentals that remain critical to limb preservation: early intervention, vascular assessment and revascularization when necessary, meticulous wound-bed preparation, infection and biofilm management, moisture balance, and—perhaps most importantly—offloading. The episode also explores where wound care may be headed over the next decade, including new Lavior formulations incorporating collagen and calcium alginate, and the growing need for clinicians who understand chronic wounds and amputation prevention. And in one of the episode’s most memorable moments, Dr. Hanley shares a powerful message for people living with diabetes: “You can either have diabetes, or it can have you.” From the science of chronic inflammation to the human impact of amputation, this episode asks an essential LIMBWatch question: How early can we intervene—and what can we do differently to preserve the limb before the wound becomes a life-changing event? Episode Description Chronic wounds don’t just threaten skin—they can threaten mobility, independence, quality of life, and ultimately the limb. In this episode of LIMBWatch, we sit down with the Lavior team to explore a different approach to chronic wound healing and limb preservation. We discuss the science behind Lavior’s Inula viscosa-derived technology, its proposed antimicrobial and anti-inflammatory properties, the role of chronic inflammation in stalled wounds, and how the product is being incorporated into the management of diabetic foot ulcers and other complex wounds. We also tackle the clinical realities that matter beyond any dressing: early intervention, wound-bed preparation, vascular status, offloading, infection control, and multidisciplinary limb-salvage care. From diabetic foot ulcers and surgical wounds to ischemic wounds, pressure injuries, burns, and difficult-to-heal wounds, this conversation examines where innovation may fit into modern wound care—and where the fundamentals of limb preservation remain non-negotiable. Because saving a limb doesn’t start at amputation. It starts much earlier. 🎙️ LIMBWatch | Diabetic Foot Files This episode is for educational purposes and does not constitute medical advice or an endorsement of any specific product. Clinical decisions should be based on individual patient assessment and the available evidence.
